Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection
Lerma-Chippirraz, Elisabet (Universitat Autònoma de Barcelona. Departament de Medicina)
Güerri-Fernández, Robert (Institut Hospital del Mar d'Investigacions Mèdiques)
Villar García, Judit (Hospital del Mar (Barcelona, Catalunya))
Gonzalez-Mena, Alicia (Hospital del Mar (Barcelona, Catalunya))
Guelar Grinberg, Ana (Hospital del Mar (Barcelona, Catalunya))
Montero, María Milagro (Universitat Autònoma de Barcelona. Departament de Medicina)
Sorlí, Luisa (Hospital del Mar (Barcelona, Catalunya))
Calzado, Sonia (Hospital del Mar (Barcelona, Catalunya))
Horcajada, Juan Pablo (Hospital del Mar (Barcelona, Catalunya))
Díez Pérez, Adolfo (Universitat Autònoma de Barcelona. Departament de Medicina)
Knobel Freud, Hernando (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2016
Resum:	Hypovitaminosis D and secondary hyperparathyroidism are frequent among HIV-infected patients. As there are no data about the best supplementation therapy both in treatment and in maintenance, we conducted an observational study of 300 HIV-infected patients for whom vitamin D and parathormone (PTH) had been measured in order to validate a protocol of vitamin D supplementation in patients with HIV-infection. Patients with vitamin D deficiency (defined as 25(OH)D < 10 ng/mL), insufficiency (defined as 25(OH)D < 20 ng/mL), or hyperparathyroidism (PTH > 65 pg/mL) were supplemented with cholecalciferol 16. 000IU (0. 266 mg) weekly (if deficiency) or fortnightly (if insufficiency or high PTH levels). Rates of normalization of 25(OH)D (levels above 20 ng/mL) and PTH levels (<65 pg/mL) were analyzed. Multivariate analysis of factors related to normalization was carried out. With a median follow-up of 2 years, 82. 1% of patients with deficiency and 83. 9% of cases with insufficiency reached levels above 20 ng/mL. However, only 67. 2% of individuals with hyperparathyroidism at baseline reached target levels (<65 pg/mL). Independent factors for not achieving PTH objective were tenofovir (TDF) and protease inhibitors use. In HIV-infected patients with hypovitaminosis, the protocol of cholecalciferol supplementation normalized vitamin D levels regardless of antiretroviral regimen in a high proportion of patients but it was less effective to correct hyperparathyroidism.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	AIDS Research and Treatment, Vol. 2016 (september 2016) , ISSN 2090-1259

DOI: 10.1155/2016/5120831
PMID: 27699068

8 p, 572.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats